A Longitudinal Evaluation of a Radiotracer for Use in Tau Tracking
Status:
Enrolling by invitation
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This is a longitudinal, observational study evaluating the imaging characteristics of the tau
PET radioligand [18F]MK-6240 in Alzheimer's disease (AD), Mild Cognitive Impairment (MCI) and
Healthy Volunteer (HV) subjects. Up to 42 subjects, including approximately 28 MCI/mild AD
subjects, up to 5 moderate AD subjects, and 9 similarly aged HV subjects will be consented
and screened. Imaging procedures include [11C]PiB to evaluate amyloid deposition,
[18F]MK-6240 PET, and structural MRI. All subjects complete an evaluable baseline
[18F]MK-6240 PET scan, as well as scans at 6, 12 and 24 months post-baseline. If unable to
complete the 6 month, 12 month, or 24 month visit, an 18 month and/or 30 month visit may
instead be scheduled, totaling a maximum of four time points.